Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Hutchison China MediTech stock

Own Hutchison China MediTech stock in just a few minutes.

Hutchison China MediTech Limited is a biotechnology business based in the US. Hutchison China MediTech shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Hutchison China MediTech employs 1,280 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Hutchison China MediTech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HCM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Hutchison China MediTech share price

Use our graph to track the performance of HCM stocks over time.

Hutchison China MediTech shares at a glance

Information last updated 2021-04-30.
52-week range$19.77 - $37.00
50-day moving average $28.75
200-day moving average $30.90
Wall St. target price$40.01
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.66

Buy Hutchison China MediTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Hutchison China MediTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hutchison China MediTech financials

Revenue TTM $228 million
Gross profit TTM $-135,319,000
Return on assets TTM -20.67%
Return on equity TTM -27.77%
Profit margin -55.15%
Book value $3.34
Market capitalisation $4.3 billion

TTM: trailing 12 months

Shorting Hutchison China MediTech shares

There are currently 829,953 Hutchison China MediTech shares held short by investors – that's known as Hutchison China MediTech's "short interest". This figure is 2.2% down from 848,568 last month.

There are a few different ways that this level of interest in shorting Hutchison China MediTech shares can be evaluated.

Hutchison China MediTech's "short interest ratio" (SIR)

Hutchison China MediTech's "short interest ratio" (SIR) is the quantity of Hutchison China MediTech shares currently shorted divided by the average quantity of Hutchison China MediTech shares traded daily (recently around 146118.48591549). Hutchison China MediTech's SIR currently stands at 5.68. In other words for every 100,000 Hutchison China MediTech shares traded daily on the market, roughly 5680 shares are currently held short.

However Hutchison China MediTech's short interest can also be evaluated against the total number of Hutchison China MediTech shares, or, against the total number of tradable Hutchison China MediTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hutchison China MediTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hutchison China MediTech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Hutchison China MediTech shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Hutchison China MediTech.

Find out more about how you can short Hutchison China MediTech stock.

Hutchison China MediTech share dividends

We're not expecting Hutchison China MediTech to pay a dividend over the next 12 months.

Have Hutchison China MediTech's shares ever split?

Hutchison China MediTech's shares were split on 29 May 2019.

Hutchison China MediTech share price volatility

Over the last 12 months, Hutchison China MediTech's shares have ranged in value from as little as $19.77 up to $37. A popular way to gauge a stock's volatility is its "beta".

HCM.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hutchison China MediTech's is 0.6711. This would suggest that Hutchison China MediTech's shares are less volatile than average (for this exchange).

Hutchison China MediTech overview

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma and soft tissue sarcoma, neuroendocrine neoplasms, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. Hutchison China MediTech Limited has collaboration agreement with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co.

Frequently asked questions

What percentage of Hutchison China MediTech is owned by insiders or institutions?
Currently 1.596% of Hutchison China MediTech shares are held by insiders and 32.639% by institutions.
How many people work for Hutchison China MediTech?
Latest data suggests 1,280 work at Hutchison China MediTech.
When does the fiscal year end for Hutchison China MediTech?
Hutchison China MediTech's fiscal year ends in December.
Where is Hutchison China MediTech based?
Hutchison China MediTech's address is: Cheung Kong Center, Central, Hong Kong
What is Hutchison China MediTech's ISIN number?
Hutchison China MediTech's international securities identification number is: US44842L1035
What is Hutchison China MediTech's CUSIP number?
Hutchison China MediTech's Committee on Uniform Securities Identification Procedures number is: 44842L103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site